You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,486,525


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,486,525
Title:Anti-neoplastic compositions comprising extracts of black cohosh
Abstract: The present invention provides a composition for use in treating or preventing neoplasia, comprising an effective actein. The present invention also provides a composition for use in treating or preventing neoplasia, comprising an effective anti-neoplastic amount of an ethyl acetate extract of black cohosh. The present invention further provides a combination of anti-neoplastic agents, comprising an effective anti-neoplastic amount of an ethyl acetate extract of black cohosh and an effective anti-neoplastic amount of at least one additional chemopreventive or chemotherapeutic agent. Methods for treating and preventing neoplasia are also provided.
Inventor(s): Einbond; Linda Saxe (Crestwood, NY), Weinstein; I. Bernard (New York, NY)
Assignee: The Research Foundation of the City University of New York (New York, NY)
Application Number:13/208,962
Patent Claims:1. A composition for use in treating neoplasia, comprising an effective anti-neoplastic amount of actein, and an effective anti-neoplastic amount of at least one additional chemotherapeutic agent, wherein the at least one additional chemotherapeutic agent is selected from the group consisting of cisplatin, doxorubicin, 5-fluorouracil, herceptin, paclitaxel, and tamoxifen, wherein the amount of actein is about 0.2 .mu.g/ml to 20.0 .mu.g/ml; and wherein the amount of cisplatin is about 2 .mu.g/ml to 20 .mu.g/ml, the amount of doxorubicin is about 0.02 .mu.g/ml to 0.2 .mu.g/ml, the amount of 5-fluorouracil is about 0.002 .mu.g/ml to 0.2 .mu.g/ml, the amount of herceptin is about 0.8 .mu.g/ml to 32 .mu.g/ml, the amount of tamoxifen is about 2 .mu.g/ml to 50 .mu.g/ml, and the amount of paclitaxel is about 0.5 nM to 5 nM.

2. The composition of claim 1, wherein the neoplasia is a carcinoma, a lymphocytic leukemia, a myeloid leukemia, a malignant lymphoma, a malignant melanoma, a myeloproliferative disease, a sarcoma, a brain tumor, a childhood tumor, or a mixed type of neoplasia.

3. The composition of claim 2, wherein the carcinoma is a breast carcinoma or a colon carcinoma.

4. The composition of claim 1, wherein the chemotherapeutic agent is paclitaxel, wherein the amount of actein is between about 0.5 .mu.g/ml to about 5 .mu.g/ml, and the amount of paclitaxel is between about 0.5 nM to about 5 nM.

5. The composition of claim 1, wherein the chemotherapeutic agent is herceptin, wherein the amount of actein is between about 0.2 .mu.g/ml to about 2 .mu.g/ml, and the amount of herceptin is about 8 .mu.g/ml to 32 .mu.g/ml.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.